Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Gains from Sales and Divestitures: 2013-2025

Historic Gains from Sales and Divestitures for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $372,218.

  • Amphastar Pharmaceuticals' Gains from Sales and Divestitures fell 4.23% to $372,218 in Q3 2025 from the same period last year, while for Sep 2025 it was $372,218, marking a year-over-year decrease of 4.23%. This contributed to the annual value of $388,816 for FY2024, which is 11.73% down from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Gains from Sales and Divestitures stood at $372,218, which was up 1.19% from $367,827 recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Gains from Sales and Divestitures registered a high of $493,718 during Q4 2021, and its lowest value of $338,280 during Q1 2025.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $388,668 (2024), whereas its average is $390,597.
  • In the last 5 years, Amphastar Pharmaceuticals' Gains from Sales and Divestitures decreased by 21.70% in 2021 and then climbed by 0.01% in 2022.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Gains from Sales and Divestitures stood at $493,718 in 2021, then fell by 3.17% to $478,068 in 2022, then decreased by 7.86% to $440,484 in 2023, then declined by 11.73% to $388,816 in 2024, then decreased by 4.23% to $372,218 in 2025.
  • Its Gains from Sales and Divestitures was $372,218 in Q3 2025, compared to $367,827 in Q2 2025 and $338,280 in Q1 2025.